Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iopofosine I 131 single dose · 1 trial · 9 indications
Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma
Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment
| Arm | Type | Description |
|---|---|---|
| Iopofosine I 131, intravenous administration WM | EXPERIMENTAL | Iopofosine I 131 in Waldenstroms Macroglobulinemia |
| Iopofosine I 131, intravenous administration MM | EXPERIMENTAL | Iopofosine I 131 in Multiple Myeloma |
| Iopofosine I 131, intravenous administration CNS Lymphoma | EXPERIMENTAL | Iopofosine I 131 in Central Nervous System Lymphoma |
| Iopofosine I 131 intravenous administration NHL [CLOSED] | EXPERIMENTAL | Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma |
| Name | Type | Description |
|---|---|---|
| Iopofosine I 131 single dose | DRUG | Radiopharmaceutical |
| Iopofosine I 131 multiple dose | DRUG | Radiopharmaceutical |
| Iopofosine I 131 fractionated dose | DRUG | Radiopharmaceutical |
\[CLOVER-1\] Inclusion Criteria: All Patients * Histologically or cytologically confirmed MM; Patients with primary or secondary CNSL may be enrolled. * ECOG performance status of 0 to 2 * 18 years of age or older * Life expectancy of at least 6 months * Platelets ≥ 75,000/µL (if full-dose anticoag...